Industrials sector | Integrated Freight & Logistics industry
| Price | $9.44 |
|---|---|
| Shares Outstanding | 50.07M |
| Net Current Assets / Share | $4.47 |
| Net Tangible Assets / Share | $6.98 |
| Max Earning Power / Share | $0.08 |
| Adjusted Earning Power |
$-1.32
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
1.37%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Ave Max Earning Power (5Y) | $0.00 |
| Ave Max Earning Power (5Q Annualized) | $2.03 |
| Ave Max Earning Power Delta (5Q Ann - 5Y) | $2.03 |
| Net Cash / Share | $3.34 |
| Dividend indicators | Value | Date |
|---|---|---|
| Pays Dividend | No | 12-19-2025 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | Yes | 12-19-2025 |
| Net Income Positive | No | 12-19-2025 |
| Avg CA Burn (Annual %) | -28.12% | 12-19-2025 |
| Avg CA Burn (Quarterly %) | 7.35% | 12-19-2025 |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2025-11-10 | 50,068,904 | +1,936 |
| 2025-09-22 | 50,066,968 | -32 |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.